Navigation Links
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
Date:9/3/2008

September is National Vascular Disease Awareness Month

CHARLOTTESVILLE, Va., Sept. 3 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). The trial, designated NCT00725881 on the clinicaltrials.gov Website, is investigating TSC as a treatment for peripheral arterial disease (PAD) patients who experience the severe leg pain known as intermittent claudication. According to the PAD Coalition, approximately 8 million Americans suffer from the disease. Results from the trial are expected to be announced in early 2010.

This double-blinded, placebo-controlled trial will randomize up to 48 patients at five research sites in the U.S. Primary clinical endpoints of the study are peak walking time and claudication onset time, as demonstrated by exercise treadmill tests. Both endpoints are well-accepted by the medical community and regulatory authorities as reliable indicators of efficacy in intermittent claudication clinical trials. Safety and pharmacokinetic assessments are also being conducted during the trial.

"In addition to advancing a much-needed treatment for peripheral arterial disease patients, this Phase I/II study will also help demonstrate TSC's potential to treat other diseases related to cellular oxygen deprivation," says David G. Kalergis, JD/MBA, Chief Executive Officer of Diffusion Pharmaceuticals. "Such proof-of-concept in humans is a critical step in the advancement of our novel pharmaceutical and will support our plans to apply it to treatments for a broad range of unmet medical needs affecting millions of patients annually."

TSC is the company's lead candidate in a family of first-in-class compounds, representing a new approach to the treatment of conditions characterized b
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Boston Scientific Corporation (NYSE: BSX ) is ... May 21-24 in Paris . ... and diversified set of data this year at EuroPCR," ... chief medical officer, Boston Scientific.  "The primary endpoint results ... PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... and MECHELEN, Belgium , ... and AbbVie (NYSE: ABBV ) announced today ... include Crohn,s disease.  Galapagos will fund and complete a ... to facilitate rapid progression into Phase 3.  Upon successful ... will pay Galapagos $50 million.  The terms of the ...
(Date:5/16/2013)... SAN FRANCISCO , May 16, 2013  Nektar Therapeutics, ... Howard W. Robin , is scheduled to ... New York at the Sheraton New ... Eastern time. The presentation will be accessible via ... Events Calendar section of the Nektar website: http://www.nektar.com . ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... selected by the Texas Hospital Association as an endorsed ... comes following a rigorous evaluation by THA and its ... is given to companies delivering leading-edge products and services ... is only granted to those companies that have met ...
... Inc., a biomedical device company based in Santa Rosa, ... for its spinal vertebral compression fracture (VCF) technology.  The ... allowed and twelve additional patent applications pending in the ... spinal therapies and devices.   The company ...
Cached Medicine Technology:CredenceHealth the Preferred Solution for Clinical Surveillance in TX, OK 2Osseon Receives Second Patent Allowance for Minimally Invasive Vertebral Compression Fracture Treatment Devices 2
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... New York, NY (PRWEB) May 18, 2013 ... of consistent efforts, SizeItUp formally announced the integration ... The redesigned 2012 Hyundai Genesis is set to stun the ... comfort and style. 2012 Hyundai Genesis is marked as the ... database and heads the vehicles lined up for the year ...
(Date:5/18/2013)... 18, 2013 Although obesity is associated ... association between obesity and esophageal adenocarcinoma, a type of ... tumors. As reported on Cancer.gov, last reviewed ... twice as likely as those of normal and healthy ... between obesity and esophageal cancer is not well understood, ...
(Date:5/18/2013)... TX (PRWEB) May 18, 2013 Show And ... years of various different training systems that is all about ... has caught the attention of http://ShowAndGoTrainingReview.com ’s Stan ... Training is a unique “four phase system” designed to ... minimum amount of time spent working out in the gym. ...
(Date:5/18/2013)... Losing weight remains to be the biggest challenge for ... weight loss products available in the market today, Garcinia Cambogia ... newest weight loss supplement prove that dieting and exercising aren’t ... is a sub-tropical fruit that is shaped like a pumpkin ... a person’s appetite, while it effectively burns fat at the ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... TONBRIDGE, England, Aug. 21 Medicine shortages have left ... being admitted to hospital, a Chemist+Druggist (C+D) survey has found. , ... responded, almost a third said patients had already suffered because the ... Pharmacists have reported growing difficulty getting hold of key ...
... , AUSTIN, Texas, Aug. 21 ... to deliver the most sophisticated point of care cell separation ... defines a new standard for isolation and retrieval of bone ... high (> 90%) mononuclear cell recovery and allows for easy ...
... , , , WOONSOCKET, R.I., ... million in just 21 days through its annual in-store fundraising campaign ... fundraising effort which, to date, has raised $19.3 million for ALS ... CVS/pharmacy locations nationwide from June 7 to 27. , , ...
... ... ... MesoRC.com, an online community and resource center developed to assist those affected by ... information with the introduction of Twitter. The goal is to provide an additional support ...
... , , SAN FRANCISCO, Aug. ... Cosmetology, a Paul Mitchell Partner School, is presenting SOMA Pet Day on Saturday, ... for The San Francisco SPCA. , , "The SF/SPCA is ... President of The SF/SPCA said today. "Community projects like this are a ...
... helps prevent disease, but a new study from Canada ... inappropriate antibiotic use. The findings come from a new ... Clinical Infectious Disease , which is now available online. ... introduced a universal immunization program offering free influenza vaccines ...
Cached Medicine News:Health News:Distressed Patients Suffer Panic Attacks as UK Medicine Stocks Hit by Shortages, Chemist+Druggist Reveals 2Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 2Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 3Health News:CVS/pharmacy Raises $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:CVS/pharmacy Raises $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 3Health News:Mesothelioma Resource Center Enters Twitter World 2Health News:Looking Good! SOMA Pet Day Benefit for San Francisco SPCA Hosted by the San Francisco Institute of Esthetics & Cosmetology Saturday, August 22, 2009 2
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: